Adam Guskich, Co-Founder and CEO of Medigrowth, looks at the innovative market opportunity that is medicinal cannabis for pets.
The pet care sector is no stranger to innovation. From advanced nutrition to cutting-edge health treatments, the industry is continuously evolving to meet pet owners growing needs. Yet one emerging area holds incredible promise and could redefine how we care for our animals: medicinal cannabis. As more pet owners seek natural and holistic solutions to manage conditions like chronic pain, anxiety, and mobility issues, medicinal cannabis offers a compelling option that is gaining momentum in the market.
Kindred, developed by Medigrowth, is pioneering the next frontier of pet health with a range of high-quality medicinal cannabis products. These products harness the power of cannabidiol (CBD), a non-psychoactive compound found in cannabis, to address common health issues in pets safely and effectively. Early studies have shown that CBD can help with pain relief, reduce anxiety, improve joint health, and even alleviate seizure activity in pets, offering an exciting alternative to traditional treatments that often come with unwanted side effects.
The demand for alternative therapies is rapidly growing. Pet owners are increasingly becoming aware of the therapeutic potential of cannabis, driven by rising interest in natural health solutions. Cannabis products for pets, particularly CBD-based treatments, have emerged as a rapidly growing category in the pet industry. According to the 2023 report from Grand View Research, the global CBD pet market size was estimated at USD 248.39 million in 2023 and is expected to grow at a CAGR of 32.47 per cent from 2024 to 2030 to over $1.7 billion. This rapid growth demonstrates that the demand for cannabis-based pet products is not a passing trend but a fundamental shift in how pet health is managed.
The benefits of medicinal cannabis for pets are becoming clearer every year. CBD is being researched for its ability to help manage the symptoms of arthritis in senior pets, ease stress in animals prone to separation anxiety, and reduce inflammation without the adverse effects commonly associated with pharmaceuticals. Many pet owners who have used CBD for their animals have reported positive results, ranging from increased mobility to more relaxed behaviour and an overall improved quality of life.
Kindred by Medigrowth is committed to quality and science, leading the charge to bring these products to market with the highest safety standards. Kindred’s mission is to provide pet owners with effective, natural remedies and to be a thought leader in this evolving space. With the backing of forward-thinking initiatives like Kindred, we can accelerate research and product development that will continue to reshape the future of pet care.
To that end, Medigrowth is currently running a crowdfunding campaign to bring innovative initiatives like Kindred’s to the forefront of the pet wellness space. This funding will allow Medigrowth to expand Kindred’s product offerings, enhance our research capabilities, and most importantly, ensure that pets everywhere can benefit from the wellness that medicinal cannabis has to offer. This is a pivotal moment in the growth of both the cannabis and pet care industries and an opportunity for Australians to be part of the market growth.
The pet industry is at a crossroads, with an increasing demand for alternative health solutions that are safe, natural, and effective. The market opportunity is immense—both for companies in the sector and for pet owners who want the best for their animals. As we look to the future, it’s clear that medicinal cannabis will play an important role in improving the health and lives of our pets.
Kindred by Medigrowth, is now offering Australians the opportunity to invest in the power of plant medicine through its crowdfunding campaign on Birchal. Kindred is proud to be leading the way and helping the industry to explore the potential of cannabis to bring positive change to the world of pet care.
This article was written by Adam Guskich, Co-Founder and CEO of Medigrowth.